Article Text

Download PDFPDF
Case-control study
Combined oral contraceptives and risk of venous thromboembolism: there is higher risk in new generations compared to second generations, but paradoxically not in norgestimate-containing-pills
  1. Geneviève Plu-Bureau
  1. Department of Gynecology, Hopitaux Universitaires Paris Centre, Paris Descartes University, Paris, France
  1. Correspondence to : Dr Geneviève Plu-Bureau, Department of Gynecology, Hopitaux Universitaires Paris Centre, 53 avenue de l'observatoire, Paris 75014, France; genevieve.plu-bureau{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: OpenUrlAbstract/FREE Full Text


For many years, it has been well documented that combined oral contraceptives (COCs) increase the risk of venous thromboembolism events (VTEs). The VTE risk may vary according to different characteristics of COCs, such as oestrogen dose and type of progestins. COCs are some of the most commonly proposed birth control methods, used by several million women worldwide. Formulations of COCs have dramatically changed over the past 50 years. The new combinations containing cyproterone, drospirenone or norgestimate, associated with low doses of ethinyl-oestradiol, have been recently investigated, but some studies have insufficient power to estimate the risks for these recent …

View Full Text


  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.